Eurofarma and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies
Published in: October 10, 2018
and updated in: November 4, 2021
Listen to the text
Stop the audio
TORONTO, ON, CANADA (October 10, 2018) – Eurofarma and Cyclica are pleased to announce a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology.
Through a multi-phase collaboration, Eurofarma will leverage Cyclica’s cloud-based proteome screening platform, Ligand Express®, to investigate the off-target profiles of small molecules, apply Cyclica’s novel and proprietary advanced AI-driven ADMET-Prediction technology to create state of the art predictive models for pharmacokinetic properties, and leverage Cyclica’s next generation AI-based de novo differential drug design (DDD) technology for multi-targeted drug design.
Dr. Martha Penna, Vice President of Innovation at Eurofarma commented, “Eurofarma is on the cutting edge of innovation, and the application of biophysics and artificial intelligence is core to our strategy of designing better medicines. We’ve had the opportunity to work with, and get to know Cyclica over the past 1.5 years, and we believe that this collaboration will enable us to achieve our drug discovery goals.”
Dr. Gabriela Barreiro, Manager, Pre-Clinical Development at Eurofarma, added, “As scientists, we are constantly looking for new ways to generate and leverage high quality data to support a more efficient discovery process. Eurofarma ‘s focus on radical innovation aligns well with Cyclica’s vision, and their set of AI-augmented technologies will be core to our we design, optimize and understand off-target profiling of lead molecules for our SGC-UNICAMP project. We are confident that these molecules will benefit patients suffering from parasitic infection like Nontuberculous Mycrobacteria (NTM)”.
Naheed Kurji, President and CEO of Cyclica said, “We are thrilled to evolve our relationship with Eurofarma through this impactful collaboration. With Dr. Penna’s leadership, Dr. Barreiro’s background in computational chemistry and previous experience, Eurofarma truly is open to new innovation and leading the charge in adopting novel computational approaches to drug discovery."
About Eurofarma Brazil
With 46 years of existence, the Eurofarma Group is the first Brazilian pharmaceutical multinational with 100% national capital, being recognized by the medical community and society for promoting access to health and quality of life with a fair price, quality and innovation treatments.
Present in 20 countries, it operates in the Medical Prescription and Prescription-Free, Generic, Hospital, Bids, Oncology, Veterinary and Services to Third-party segments. In Brazil, the portfolio is represented by 335 brands in 844 presentations, including 28 medical specialties and 148 therapeutic classes.
For more information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
Media Inquires:
Stephanie Van Sebroeck +55 11 5090-8600 ext.8369 – stephanie@gaspar.com.br
Guilherme Gaspar +55 11 3065-3045 – guilherme@gaspar.com.br
About Cyclica
Cyclica is a Toronto-based biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalize medicines. To learn more, visit https://www.cyclicarx.com
Media Inquires:
Naheed Kurji
President and CEO
Cyclica Inc
mailto:naheed.kurji@cyclicarx.com
Through a multi-phase collaboration, Eurofarma will leverage Cyclica’s cloud-based proteome screening platform, Ligand Express®, to investigate the off-target profiles of small molecules, apply Cyclica’s novel and proprietary advanced AI-driven ADMET-Prediction technology to create state of the art predictive models for pharmacokinetic properties, and leverage Cyclica’s next generation AI-based de novo differential drug design (DDD) technology for multi-targeted drug design.
Dr. Martha Penna, Vice President of Innovation at Eurofarma commented, “Eurofarma is on the cutting edge of innovation, and the application of biophysics and artificial intelligence is core to our strategy of designing better medicines. We’ve had the opportunity to work with, and get to know Cyclica over the past 1.5 years, and we believe that this collaboration will enable us to achieve our drug discovery goals.”
Dr. Gabriela Barreiro, Manager, Pre-Clinical Development at Eurofarma, added, “As scientists, we are constantly looking for new ways to generate and leverage high quality data to support a more efficient discovery process. Eurofarma ‘s focus on radical innovation aligns well with Cyclica’s vision, and their set of AI-augmented technologies will be core to our we design, optimize and understand off-target profiling of lead molecules for our SGC-UNICAMP project. We are confident that these molecules will benefit patients suffering from parasitic infection like Nontuberculous Mycrobacteria (NTM)”.
Naheed Kurji, President and CEO of Cyclica said, “We are thrilled to evolve our relationship with Eurofarma through this impactful collaboration. With Dr. Penna’s leadership, Dr. Barreiro’s background in computational chemistry and previous experience, Eurofarma truly is open to new innovation and leading the charge in adopting novel computational approaches to drug discovery."
About Eurofarma Brazil
With 46 years of existence, the Eurofarma Group is the first Brazilian pharmaceutical multinational with 100% national capital, being recognized by the medical community and society for promoting access to health and quality of life with a fair price, quality and innovation treatments.
Present in 20 countries, it operates in the Medical Prescription and Prescription-Free, Generic, Hospital, Bids, Oncology, Veterinary and Services to Third-party segments. In Brazil, the portfolio is represented by 335 brands in 844 presentations, including 28 medical specialties and 148 therapeutic classes.
For more information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
Media Inquires:
Stephanie Van Sebroeck +55 11 5090-8600 ext.8369 – stephanie@gaspar.com.br
Guilherme Gaspar +55 11 3065-3045 – guilherme@gaspar.com.br
About Cyclica
Cyclica is a Toronto-based biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalize medicines. To learn more, visit https://www.cyclicarx.com
Media Inquires:
Naheed Kurji
President and CEO
Cyclica Inc
mailto:naheed.kurji@cyclicarx.com